Table 9.
Slo family selectivity for select SLACK inhibitors
| No. | SLICK (Slo2.1) | Maxi-K (Slo1 α1/β3) | ||
|---|---|---|---|---|
| IC50 (μM)a | Efficacy (%)a,b | IC50 (μM)a | Efficacy (%)a,b | |
|
| ||||
| 5 | >10c | 55 | inactive | |
| 27 | >10c | 47 | inactive | |
| 43 | 2.3 | 50 | inactive | |
| 58 | >10c | 44 | inactive | |
| 60 | >10c | 65 | inactive | |
| 76 | >10c | 35 | inactive | |
| 109 | >10c | 55 | inactive | |
| 113 | >10c | 27 | inactive | |
| 119 | >10c | 55 | inactive | |
| 121 | 5.9 | 56 | inactive | |
| 122 | >10c | 76 | inactive | |
a
CRC from Tl+ flux assay in HEK-293 cells expressing either SLICK (Slo2.1) or Maxi-K (Slo1 α1/β3)
b
Amplitude of response in the presence of 30 μM test compound as a percentage of the maximum response for SKF96365 (SLICK) or paxilline (Maxi-K)
c
CRC does not plateau